What is the share price of Marksans Pharma Ltd (MARKSANS) today?
The share price of MARKSANS as on 22nd May 2025 is ₹246.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Marksans Pharma Ltd (MARKSANS) share?
The past returns of Marksans Pharma Ltd (MARKSANS) share are- Past 1 week: 5.56%
- Past 1 month: 16.56%
- Past 3 months: 9.18%
- Past 6 months: -20.04%
- Past 1 year: 48.01%
- Past 3 years: 403.67%
- Past 5 years: 1155.98%
What are the peers or stocks similar to Marksans Pharma Ltd (MARKSANS)?
The peers or stocks similar to Marksans Pharma Ltd (MARKSANS) include:What is the dividend yield % of Marksans Pharma Ltd (MARKSANS) share?
The current dividend yield of Marksans Pharma Ltd (MARKSANS) is 0.32.What is the market cap of Marksans Pharma Ltd (MARKSANS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Marksans Pharma Ltd (MARKSANS) is ₹11184.08 Cr as of 22nd May 2025.What is the 52 week high and low of Marksans Pharma Ltd (MARKSANS) share?
The 52-week high of Marksans Pharma Ltd (MARKSANS) is ₹358.70 and the 52-week low is ₹130.What is the PE and PB ratio of Marksans Pharma Ltd (MARKSANS) stock?
The P/E (price-to-earnings) ratio of Marksans Pharma Ltd (MARKSANS) is 29.39. The P/B (price-to-book) ratio is 5.36.Which sector does Marksans Pharma Ltd (MARKSANS) belong to?
Marksans Pharma Ltd (MARKSANS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Marksans Pharma Ltd (MARKSANS) shares?
You can directly buy Marksans Pharma Ltd (MARKSANS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Marksans Pharma Ltd
MARKSANS Share Price
246.801.36% (-3.41)
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
MARKSANS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 29.39 | 5.36 | 0.32% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.78 | 6.46 | 0.86% |
MARKSANS Analyst Ratings & Forecast
Detailed Forecast 100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
MARKSANS Company Profile
Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.
Investor Presentation
View olderMARKSANS Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
37.73
1Y Return
11.65%
Buy Reco %
88.24
CIPLA
PE Ratio
22.49
1Y Return
0.93%
Buy Reco %
75.00
TORNTPHARM
PE Ratio
56.89
1Y Return
20.58%
Buy Reco %
72.00
DRREDDY
PE Ratio
17.98
1Y Return
4.06%
Buy Reco %
53.33
MANKIND
PE Ratio
50.56
1Y Return
15.76%
Buy Reco %
81.25
MARKSANS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
MARKSANS Stock Summary · February 2025
In Q3 FY25, the company demonstrated robust financial performance with a 16.3% year-on-year revenue growth, driven primarily by a remarkable 37% increase in the U.S. market. Despite challenges in Australia and New Zealand due to seasonal factors and geopolitical issues affecting other regions, the company achieved an all-time high profit after tax of INR 105 crores. However, rising freight and employee costs have pressured EBITDA margins, which are stabilizing around 21%. Looking ahead, management is optimistic about future growth, particularly with the ramp-up of a new manufacturing facility and strategic initiatives aimed at reaching a revenue target of INR 4,000 crores. The company remains debt-free with a strong cash position, allowing for continued investment in innovation and operational efficiency.
Key Points on Marksans Stock
MARKSANS Stock Growth Drivers
6Strong Financial Performance
The company reported a 16.3% year-on-year revenue growth in Q3 FY25, marking the 12th consecutive
Operational Efficiency and Margin Improvement
The company experienced gross margin expansion due to an improved product mix and lower raw
MARKSANS Stock Challenges
5Declining Margins and Cost Pressures
The company has experienced a decline in EBITDA margins, attributed to increased employee and freight
Geopolitical and Market Risks
Revenue from the Rest of the World was impacted by geopolitical issues, highlighting the vulnerability
MARKSANS Forecasts
MARKSANS Forecast
Price
Revenue
Earnings
MARKSANS Share Price Forecast
2025
Current
₹246.80
Baseline
Forecast for May 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹246.80
Baseline
Forecast for May 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
MARKSANS Company Revenue Forecast
2025
Current
₹2.69
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹2.69
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
MARKSANS Stock EPS (Earnings Per Share) Forecast
2025
Current
₹8.40
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹8.40
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
MARKSANS
Income
Balance Sheet
Cash Flow
Annual Normal View
MARKSANS Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 774.18 | 921.16 | 1,004.69 | 1,134.54 | 1,382.87 | 1,532.69 | 1,911.45 | 2,227.83 | 2,693.22 | 2,693.23 | ||||||||||
Raw Materials | 506.68 | 502.58 | 517.91 | 514.88 | 731.33 | 703.92 | 927.75 | 1,111.98 | 2,094.21 | 2,094.20 | ||||||||||
| Power & Fuel Cost | 12.97 | 11.55 | 13.99 | 14.00 | 16.42 | 18.59 | 24.50 | 36.94 | ||||||||||||
| Employee Cost | 149.70 | 147.75 | 159.07 | 168.42 | 197.32 | 220.30 | 239.37 | 293.64 | ||||||||||||
| Selling & Administrative Expenses | 65.18 | 88.83 | 109.58 | 120.38 | 154.55 | 148.41 | 227.00 | 236.41 | ||||||||||||
| Operating & Other expenses | -12.12 | 83.60 | 67.38 | 124.28 | -63.05 | 140.74 | 94.20 | 39.86 | ||||||||||||
EBITDA | 51.77 | 86.85 | 136.76 | 192.58 | 346.30 | 300.73 | 398.63 | 509.00 | 599.01 | 599.03 | ||||||||||
| Depreciation/Amortization | 30.09 | 26.84 | 22.80 | 26.66 | 36.15 | 44.78 | 51.85 | 74.27 | 83.39 | 83.38 | ||||||||||
| PBIT | 21.68 | 60.01 | 113.96 | 165.92 | 310.15 | 255.95 | 346.78 | 434.73 | 515.62 | 515.65 | ||||||||||
| Interest & Other Items | 6.78 | 10.22 | 9.66 | 8.75 | 7.99 | 8.45 | 9.13 | 11.20 | 11.66 | 11.66 | ||||||||||
| PBT | 14.90 | 49.79 | 104.30 | 157.17 | 302.16 | 247.50 | 337.65 | 423.53 | 503.96 | 503.99 | ||||||||||
| Taxes & Other Items | 6.06 | 16.86 | 27.84 | 36.42 | 66.22 | 62.95 | 71.34 | 109.83 | 123.39 | 123.39 | ||||||||||
| Net Income | 8.84 | 32.93 | 76.46 | 120.75 | 235.94 | 184.55 | 266.31 | 313.70 | 380.57 | 380.60 | ||||||||||
| EPS | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 6.18 | 6.92 | 8.40 | 8.40 | ||||||||||
| DPS | 0.05 | 0.05 | 0.05 | 0.10 | 0.25 | 0.25 | 0.50 | 0.60 | 0.80 | 0.60 | ||||||||||
| Payout ratio | 0.23 | 0.06 | 0.03 | 0.03 | 0.04 | 0.06 | 0.08 | 0.09 | 0.10 | 0.07 |
MARKSANS Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2025
Investor Presentation
May 19PDF
Feb 11PDF
Nov 12PDF
MARKSANS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Marksans Pharma Ltd | 29.39 | 5.36 | 0.32% |
| Sun Pharmaceutical Industries Ltd | 37.73 | 6.15 | 0.93% |
| Cipla Ltd | 22.49 | 4.43 | 1.09% |
| Torrent Pharmaceuticals Ltd | 56.89 | 15.86 | 1.00% |
MARKSANS Stock Price Comparison
Compare MARKSANS with any stock or ETFCompare MARKSANS with any stock or ETF
MARKSANS
MARKSANS Shareholdings
MARKSANS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
MARKSANS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
MARKSANS Shareholding Pattern
MARKSANS Shareholding History
Foreign Institutions
Mutual Funds Invested in MARKSANS
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Marksans Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4988% | Percentage of the fund’s portfolio invested in the stock 2.78% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/46 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4300% | Percentage of the fund’s portfolio invested in the stock 1.09% | Change in the portfolio weight of the stock over the last 3 months -0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 68/96 (-13) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4089% | Percentage of the fund’s portfolio invested in the stock 2.03% | Change in the portfolio weight of the stock over the last 3 months 0.47% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/45 (+9) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing MARKSANS stock
Looks like this stock is not in any smallcase yet.
MARKSANS Events
MARKSANS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
MARKSANS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.34%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.38 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
MARKSANS Upcoming Dividends
No upcoming dividends are available
MARKSANS Past Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateJun 7, 2023
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jun 7, 2023
Cash Dividend
Ex DateEx DateAug 19, 2022
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Aug 19, 2022
Cash Dividend
Ex DateEx DateSep 15, 2021
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Sep 15, 2021
Cash Dividend
Ex DateEx DateSep 22, 2020
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2020
MARKSANS Stock News & Opinions
Articles & Videos
Corporate
Board of Marksans Pharma recommends final dividend
Marksans Pharma announced that the Board of Directors of the Company at its meeting held on 19 May 2025, inter alia, have recommended the final dividend of Rs 0.8 per equity Share (i.e. 80%) , subject to the approval of the shareholders.Powered by Capital Market - Live
2 days agoCapital Market - Live
Earnings
Marksans Pharma consolidated net profit rises 15.66% in the March 2025 quarter
Net profit of Marksans Pharma rose 15.66% to Rs 90.55 crore in the quarter ended March 2025 as against Rs 78.29 crore during the previous quarter ended March 2024. Sales rose 26.51% to Rs 708.46 crore in the quarter ended March 2025 as against Rs 560.01 crore during the previous quarter ended March 2024. For the full year,net profit rose 21.32% to Rs 380.58 crore in the year ended March 2025 as against Rs 313.70 crore during the previous year ended March 2024. Sales rose 20.46% to Rs 2622.85 crore in the year ended March 2025 as against Rs 2177.41 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales708.46560.01 27 2622.852177.41 20 OPM %17.7519.58 -20.1521.06 - PBDT138.84121.33 14 587.35497.80 18 PBT116.09100.28 16 503.97423.53 19 NP90.5578.29 16 380.58313.70 21 Powered by Capital Market - Live
2 days agoCapital Market - Live
Corporate
Relonchem receives marketing authorization for Sennosides 7.5 mg tablets
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Sennosides 7.5 mg Tablets from UK Medicines & Healthcare Products Regulatory Agency.Powered by Capital Market - Live
3 days agoCapital Market - Live
Corporate
Relonchem receives marketing authorization for Gabapentin 50 mg/ml oral solution
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Marksans Pharma to conduct board meeting
Marksans Pharma will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York
Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA ('the Subsidiary') from 16 April 2025 to 24 April 2025. On conclusion of the inspection, the Subsidiary has received One (1) inspectional observation in Form 483. There is no data integrity observation. The Subsidiary will work closely with the USFDA and is committed to address the observation comprehensively within the stipulated time. Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Spotlight
Marksans Pharma gains as USFDA concludes inspection at New York unit
The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturing facility in Farmingdale, New York. At the end of the inspection, the subsidiary received one observation, documented in the USFDA's Form 483. Notably, the inspection did not raise any concerns regarding data integrity. Marksans Pharma confirmed that it will work closely with the USFDA to address the observation within the prescribed timeline. Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Marksans Pharma's Goa facility receives Australian TGA approval
Marksans Pharma announced that its manufacturing facility located at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa has been approved by Australian TGA for manufacture of pharmaceutical formulations in Solid Dosage Forms of Tablets and hard Capsules for Australian markets. The products will be manufactured at the above facility in Goa India and marketed & distributed in Australian markets through the Company's subsidiary Nova Pharmaceuticals Australasia. Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Marksans Pharma rises after receiving regulatory nod for supplying pharma products to Australia
The pharmaceutical formulations include solid dosage forms of tablets and hard capsules. The products will be manufactured at the aforementioned facility located at Verna Industrial Estate, Verna, Goa, and marketed & distributed in Australian markets through the company's subsidiary Nova Pharmaceuticals Australasia. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Relonchem receives UK MHRA marketing authorization for Baclofen 10 mg Tablets
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA.Powered by Capital Market - Live
2 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 17.27%, vs industry avg of 9.04%
Over the last 5 years, market share increased from 0.46% to 0.58%
Over the last 5 years, net income has grown at a yearly rate of 32.62%, vs industry avg of 15.28%